Mechanisms of androgen-refractory prostate cancer

New England Journal of Medicine

Volumn 351, Issue 15, 2004, Pages 1488-1490

  Debes, Jose D ^a   Tindall, Donald J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BISPHOSPHONIC ACID DERIVATIVE; CASPASE; CYTOKINE; DNA; DOCETAXEL; GROWTH FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 6; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C; STEROID; STEROID RECEPTOR; TESTOSTERONE;

ANDROGEN REFRACTORY PROSTATE CANCER; APOPTOSIS; CANCER SURVIVAL; GENE; GENETIC TRANSCRIPTION; HORMONE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 4744347762     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp048178     Document Type: Review

References (3)

1. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-5.
3. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-97.